Elastase

Other Names

bone marrow serine proteaseCELA1CELA2ACELA2BCELA3ACELA3Bchymotrypsin-like elastaseELA2ELANEelastase 1elastase 2elastase 3Aelastase 3Belastase IIAelastase IIBelastase inhibitorelaszymendopeptidase (elastin-specific)granulocyte elastaseHLEHNEhuman leukocyte elastaseleukocyte elastaselysosomal elastasemacrophage elastasemedullasinneutrophil elastasepancreatic elastasepancreatic elastase IIpancreatic elastase-1PMN elastasepolymorphonuclear leukocyte elastasepolymorphonuclear neutrophil elastaseproelastaseserine elastaseserine protease (elastin-degrading)

Synopsis

Elastase: A Comprehensive Encyclopedic Reference

1. Identity and Nomenclature

1.1 Biochemical Classification and Names

In molecular biology, elastase is an enzyme from the class of proteases (peptidases) that break down proteins — specifically one that can break down elastin. Elastase belongs to the serine proteases family, which comprises hydrolases that break down peptide bonds. The name refers exclusively to substrate specificity (the ability to digest elastin) rather than to any single evolutionary lineage of enzyme. The name refers to what proteins it can digest, not to any kind of evolutionary grouping.

Elastase is classified into two main types based on origin: pancreatic elastase and leukocyte elastase. The four "pancreatic elastases," chymotrypsin, and neutrophil elastase are serine proteases, while "macrophage elastase" is a matrix metallopeptidase. Some bacteria — including Pseudomonas aeruginosa — also produce elastase; bacterial elastases work in many ways and include serine proteases, aspartic proteases, thiol proteases, and metalloenzymes.

The chymotrypsin-like elastases (CELAs) are the principal pancreatic forms. The chymotrypsin-like elastases (CELAs) are digestive serine proteinases secreted by the pancreas. CELA1 was first described in 1949 by the Hungarian scientists Baló and Banga as an enzyme in the pig pancreas capable of hydrolyzing insoluble elastin. The human pancreas does not express CELA1 but secretes two CELA3 isoforms, CELA3A and CELA3B.

Elastase is a proteolytic enzyme belonging to the family of hydrolases produced by human neutrophils, monocytes, macrophages, and endothelial cells. Human neutrophil elastase (HNE) — also abbreviated NE or HLE (Human Leukocyte Elastase) — is the leukocyte form most widely discussed in inflammatory disease research.

1.2 Structural Characteristics

Elastase is a glycoprotein, and the polypeptide chain constitutes 218 amino acids. Elastase is biosynthesized as a proelastase containing a terminal peptide of 29 radicals. The residues His-57, Asp-102, and Ser-195 are referred to as the "catalytic triad" in the family of serine proteases. Porcine pancreatic elastase is composed of a single peptide chain of 240 amino acids and contains 4 disulfide bridges. In terms of physical chemistry, pancreatic elastase isolated from pig (Sus scrofa) is an endopeptidase with a molecular weight of 25,907.11 amu, an isoelectric point at pH 8.65, and a primary structure 240 residues long.

1.3 Natural Sources and Common Preparations

Pancreatic elastase, also known as elastase-1, is secreted by the pancreas into the duodenum, where it facilitates the digestion of proteins by cleaving their peptide bonds. This form of elastase is crucial in the digestive system, enabling the efficient breakdown and absorption of dietary proteins. Elastase is a serine protease that also hydrolyzes amides and esters. It is produced in the pancreas as an inactive zymogen and activated in the duodenum by trypsin.

Elastase has been confirmed to exist in the pancreas of most animals, including humans, monkeys, cats, and rabbits. The level is about 3.1 mg/g-pancreas in human beings, about 2.2 mg/g in bovine animals, and about 10.2 mg/g in rats.

Elastase is a cold-active enzyme that has been isolated from the Atlantic cod viscera, along with collagenase and chymotrypsin. Some fungi also produce elastase, which is utilized in various industrial processes, including the production of laundry detergents and waste treatment.

In terms of preparations, elastase is available in several forms for research, diagnostic, and pharmaceutical purposes. It is available as a lyophilized powder, stored at 2–8 °C, as well as in a twice-crystallized form supplied as a dialyzed, lyophilized powder. In the clinical and dietary supplement context, porcine-derived pancreatic elastase (derived from pig pancreas) has been the predominant commercial form studied, given that porcine elastase is the most potent elastase, having a rate 20-fold higher than that of human leukocyte elastase.

2. Historical and Traditional Use

2.1 Discovery and Early Scientific History

Elastase has no deep record of pre-scientific traditional use in the herbal medicine sense; its history is primarily one of laboratory discovery in the twentieth century. Eijkman is believed to be the first to have studied elastase as a product of bacteria (1904). However, it was not shown to differ from other proteolytic components of the pancreas, such as trypsin and chymotrypsin, until the Baló and Banga publication in 1949.

Elastases were first defined by their ability to solubilize insoluble elastin by Hungarian scientists Baló and Banga in 1949, who demonstrated the presence of such elastolytic activity in pancreatic homogenates of the pig. This discovery arose directly from clinical observation: in the course of their study on arteriosclerosis, Baló and colleagues observed degradation of the elastin fibers of blood vessel walls and postulated the presence of a degrading enzyme. Subsequently, Banga discovered an enzyme in the pancreas which specifically degrades elastin. The enzyme was isolated in the form of crystals and named "elastase."

In joint research with her husband József Baló on arteriosclerosis, Banga studied the origin of fiber degradation in vein walls, which led them to discover the enzyme elastase produced by the pancreas. In 1968, Shotton and Hartley were the first to obtain crystalline porcine elastase.

2.2 Early Clinical Interest and the Arteriosclerosis Hypothesis

Following the initial discovery, Baló and Banga themselves pursued the question of whether pancreatic elastase might be therapeutically relevant to cardiovascular disease. A correlation was recognized between elastase activity and age: a marked lowering in elastase activity in the pancreas and plasma of males over 40 and of females over 60 years was reported by Loeven and Baldwin. In the case of patients with arteriosclerosis, the elastase activity in the pancreas was reported by Baló and Banga to be markedly lower than that of healthy people, and in some cases it had completely disappeared. This observation suggested a possible link between pancreatic elastase depletion and vascular aging, though this line of therapeutic inquiry was not developed into robust clinical trials.

In the late 1960s and into the early 1970s, elastase's involvement in emphysema, atherosclerosis, and acute hemorrhagic pancreatitis was investigated. In 1974, Ardelt discovered a second elastolytic proteinase, naming it pancreatic "elastase II," with the original renamed "elastase I."

Subsequent studies also demonstrated that elastase not only catalyses the hydrolysis of elastin but also accelerates elastin biosynthesis — a finding that complicated simple models of elastase as purely destructive and pointed toward a dual physiological role.

While the foregoing represents the enzyme's scientific history, it is important to note that elastase itself has no documented ethnobotanical or traditional folk-medicine use in the sense of a botanical remedy. Its medical and supplement application is entirely a product of twentieth- and twenty-first-century biomedical science. What does have a historical record is the traditional use of plant materials — many of them later shown to contain elastase-inhibiting flavonoids — against inflammatory skin conditions and respiratory disorders in Ayurvedic, Chinese, and other herbal traditions. However, those traditional uses were attributed to the plants themselves, not to the concept of elastase inhibition, which is a modern biochemical framework.

3. Key Constituents, Molecular Biology, and Mechanisms of Action

3.1 The Catalytic Triad and Serine Protease Mechanism

Chymotrypsin, trypsin, and elastase are three well-known enzymes that operate through the serine protease mechanism of action. Each residue in the catalytic triad has a specific function. The –OH group of the serine at the active site acts as a nucleophile that attacks the carbonyl carbon of the peptide bond to be hydrolyzed. The histidine residue contains a pair of electrons that aid in the nucleophilic attack by accepting serine's hydrogen. Additionally, histidine's pair of electrons is made much more electronegative through hydrogen bonding with the carboxyl group of aspartate.

The precise hydrogen bond network that exists between these amino acid residues allows the Serine-195 hydroxyl to form a tetrahedral intermediate with the carbonyl of an amide substrate. The decomposition of this intermediate results in the release of a free amine and the acylated enzyme. In a subsequent step, this newly formed ester is hydrolyzed to give the native enzyme and the carboxylic acid.

3.2 Substrate Specificity

Elastase's unique substrate specificity distinguishes it from the other classical serine proteases. In the enzyme elastase, the specificity pocket is very small, so only proteins with relatively small amino acid side chains, such as glycine or alanine, can be cut by this enzyme. More precisely, elastases of the serine protease type preferentially break down peptide bonds on the carboxyl side of small, hydrophobic amino acids such as glycine, alanine, and valine. Because of its cationic character, CELA1 can absorb to the surface of the negatively charged elastin fibers and cleave multiple Ala-Ala and Ala-Gly peptide bonds.

Porcine elastase I is specific for Ala-Ala and Ala-Gly bonds, while elastase II has a broad specificity for substrates with medium to large hydrophobic amino acids in the P1 position. Notably, despite its name, CELA1 is not a specific elastin-degrading enzyme, and it readily digests a variety of dietary protein substrates.

3.3 Activation from Zymogen Form

The enzymes required for digestion of proteins in the duodenum — chymotrypsin, carboxypeptidase, trypsin, and elastase — are produced and stored in the pancreas as inactive precursors. Trypsin acts as a common activator of all proteolytic enzymes, and this process occurs when the zymogens enter the duodenum from the pancreas. Elastase is biosynthesized as a proelastase containing a terminal peptide of 29 radicals and 27 initiation signals; these are eliminated during biosynthesis, leading to activation; once activated, elastase is secreted as a glycoprotein that contains a serine residue in position 57 in its binding site.

3.4 Endogenous Inhibition: The Protease–Antiprotease Balance

Elastase is inhibited by the acute-phase protein α1-antitrypsin (A1AT), which binds almost irreversibly to the active site of elastase and trypsin. A1AT is normally secreted by the liver cells into the serum. Alpha-1 antitrypsin deficiency (A1AD) leads to uninhibited destruction of elastic fibre by elastase; the main result is emphysema.

The imbalance between elastase activity and its endogenous inhibitors can cause different illnesses due to their excessive activity. The alpha-1 antitrypsin (AAT) protein's main function is to inactivate neutrophil elastase (NE) upon insult to the lungs, such as smoking. In its absence, there is an imbalance of proteinases and anti-proteinases, which leads to the progression of emphysema and deterioration of lung function, resulting in COPD.

3.5 Biological Functions of Neutrophil Elastase

Under homeostatic conditions, neutrophil azurophilic granules contain serine proteases including neutrophil elastase (NE). Due to their antimicrobial and immunomodulatory function, these pre-stored catalytically active mediators play a major role in the physiological response to infection. However, their uncontrolled extracellular release may have unintended consequences by causing damage to surrounding healthy tissue.

Elastase performs several critical biological functions: as part of the digestive enzymes secreted by the pancreas, it contributes to the breakdown of dietary proteins, aiding in nutrient absorption; it helps in the remodeling of extracellular matrix proteins, facilitating tissue repair and regeneration; and leukocyte elastase plays an essential role in the immune system by degrading pathogenic proteins and contributing to the inflammatory response.

Neutrophil elastase or HLE (Human Leukocyte Elastase) is a proinflammatory agent known to be capable of degrading various components of extracellular matrix such as elastin, type III and IV collagen, and proteoglycans.

4. Scientific Evidence by Area of Use

4.1 Pancreatic Exocrine Function and Gastrointestinal Diagnostics

The most firmly established clinical application involving elastase is its use as a diagnostic biomarker rather than a therapeutic agent. Fecal pancreatic elastase measurement is used to assess exocrine pancreatic function.

Pancreatic elastase (PE) is a proteolytic enzyme produced in the pancreatic acinar cells. This test can be used for the diagnosis or the exclusion of exocrine pancreatic insufficiency (EPI), which may be associated with chronic pancreatitis, cystic fibrosis, carcinoma of the pancreas, diabetes mellitus type 1, Shwachman-Diamond syndrome, and other etiologies of pancreatic insufficiency. The enzyme stability is remarkably high despite its proteolytic activity, as elastase is found in feces in about a sixfold concentration compared to pancreatic fluid.

Pancreatic elastase concentrations below 100 mcg/g are consistent with exocrine pancreatic insufficiency. Normal concentrations of fecal pancreatic elastase (PE) do not exclude the possibility of EPI, especially in cases of mild or moderate disease. Decreased concentrations of fecal PE are not diagnostic for EPI, particularly in patients with low pre-test probability.

A systematic review and meta-analysis (2025) evaluated the diagnostic accuracy of fecal elastase-1 (FE-1) across 13 studies encompassing 888 patients. Thirteen studies with 888 patients were included. Fecal elastase-1 at a cut-off of 200 μg/g showed a pooled sensitivity and specificity of 0.94 and 0.69, respectively, with a DOR of 35.27. Lowering the cut-off to 100 μg/g improved specificity to 0.82 but decreased sensitivity to 0.88. Subgroup analyses showed different diagnostic performance in different clinical contexts, with higher sensitivity in cystic fibrosis (0.98) and higher specificity in chronic pancreatitis (0.81). The overall conclusion was that fecal elastase-1 is a sensitive and moderately specific diagnostic tool for pancreatic exocrine insufficiency and is suitable for initial screening in high-risk populations. However, its moderate specificity requires careful interpretation in lower-risk settings.

Elastase is an endopeptidase found in pancreatic juice that occurs in the circulation of normal healthy individuals in the form of its zymogen, proelastase. In acute pancreatitis, free elastase, in addition to proelastase, escapes into the circulation, and high serum concentrations persist for several days after amylase activities have returned to normal. In a recent study, the sensitivity of serum elastase-1 level for acute pancreatitis was 97% at the day of admission and 100% within 48 hours after the onset of pain.

Evidence strength: Strong for diagnostic use. The fecal elastase test is widely validated and guideline-supported (AGA, UK consensus guidelines) as an initial screening tool for EPI. Its therapeutic supplementation for digestive purposes is less studied as a standalone agent and is typically considered in the context of pancreatic enzyme replacement therapy (PERT) for EPI.

4.2 Pulmonary Disease: Emphysema, COPD, and Alpha-1 Antitrypsin Deficiency

The role of elastase in lung disease — specifically the protease–antiprotease imbalance hypothesis — is one of the most extensively studied areas in pulmonary medicine.

Pulmonary emphysema, a component of COPD, is characterised by irreversible alveolar tissue destruction and is produced by an imbalance between proteolytic enzymes, mostly neutrophil elastase (NE), and its inhibitors, mainly alpha-1 antitrypsin (AAT).

Alpha-1 antitrypsin deficiency (AATD) is a hereditary disorder first described in 1963 as a genetic cause of COPD. AATD is characterized by low levels of alpha-1 antitrypsin (AAT), allowing neutrophil elastase (NE) to destroy the elastin structure of the lung.

Over the decades since the protease pathogenesis model was first proposed, the story of cigarette smoke-induced lung disease has become more complex with a variety of additional proteases, inhibitors, inflammatory mediators, and host responses. Still, the story of COPD in AATD maintains a simpler, more direct route with neutrophil elastase maintaining a prominent role in the pathogenesis of parenchymal disease of the lung.

Among the proteases released from neutrophils, human neutrophil elastase (HNE) is particularly important. HNE levels are higher in COPD patients than normal subjects. HNE exerts various deleterious effects on lung immunity and structure, such as degradation of surfactant proteins and induction of emphysema.

Metaplasia of the airway epithelium in COPD and other airway diseases results in large numbers of goblet cells in the peripheral airways. When these goblet cells are stimulated to release their contents, the excess mucus in the airways can cause severe cough, airflow obstruction, peripheral airway plugging, and may lead to further inflammation and possibly infection.

Clinical trials have investigated NE inhibitors (not elastase supplementation but its suppression) in lung disease. The use of NE inhibitors in chronic respiratory disease (CF, bronchiectasis, or COPD) is still not supported by sufficient scientific evidence from clinical studies. However, AZD9668 induced a reduction in sputum inflammation in CF and an improvement in lung function in bronchiectasis.

A pivotal large multicenter trial, the STRIVE study, evaluated the synthetic NE inhibitor sivelestat in acute lung injury. The only large multicenter, double-blind placebo-controlled trial in patients with ALI receiving mechanical ventilation (STRIVE) showed a trend toward increased long-term mortality with sivelestat (sivelestat 40.2% vs. placebo 31.3%; P = .006). This result raised important caution about broadly inhibiting NE in the acute lung injury context.

For AATD-specific augmentation therapy (infusing purified AAT to inhibit elastase): AAT augmentation therapy has produced beneficial consequences, like ameliorating lung function decline and emphysema progression, prolonging survival, and delaying the decline in quality of life, especially in severe AATD, i.e., ZZ or Z null patients. A trial examining biomarkers confirmed that A1PI therapy reduced elastin degradation, including pulmonary elastin, in patients with AATD. These data support using DES/IDES levels as biomarkers to monitor emphysema progression and treatment response.

Evidence strength: Strong mechanistic and biomarker evidence; moderate-to-strong clinical evidence for AAT augmentation therapy in genetically confirmed severe AATD. Evidence for synthetic small-molecule NE inhibitors in COPD and ALI is inconsistent, with some major trials showing lack of benefit or harm.

4.3 Skin Aging and Dermatology

Elastase — specifically its inhibition — has emerged as an important target in cosmetic dermatology and photoaging research.

Skin aging is characterized by features such as wrinkling, loss of elasticity, laxity, and rough-textured appearance. This aging process is accompanied with phenotypic changes in cutaneous cells as well as structural and functional changes in extracellular matrix components such as collagens and elastin.

In photoaged skin, the oxytalan fibers undergo degeneration, and the elastic fibers of the upper dermis are degraded by elastolytic enzymes including MMPs and neutrophil elastases. The altered, disorganized elastic fibers gradually accumulate in the reticular dermis, appearing as solar elastosis. In contrast, intrinsic skin aging is characterized by overall depletion of the elastic fiber network.

Neutrophil elastase or HLE (Human Leukocyte Elastase) is a proinflammatory agent known to be capable of degrading various components of extracellular matrix such as elastin, type III and IV collagen, and proteoglycans. The activity of neutrophil elastase is increased on the surface of the diseased skin of patients with psoriasis, atopic dermatitis, and allergic contact dermatitis — pathologies characterized by leukocyte infiltration of the skin.

There is a paucity of clinical data reporting elastase as the target of a specific bioactive peptide in the cosmeceutical arena. One studied topical agent, SA1-III (also known as KP1), is a decapeptide formally derived from the C-terminal portion of serpin A1, a physiological inhibitor of neutrophil elastase, and has been the subject of laboratory and clinical studies determining its effects on modulation of collagen turnover as well as the treatment of age-associated changes of the face.

From a natural-products perspective, multiple plant extracts have been evaluated for their ability to inhibit elastase activity in vitro as a proxy for anti-aging potential. The leaf extracts of Anacardium occidentale and Cinnamomum zeylanicum demonstrated strong inhibitory action against both elastase and tyrosinase enzymes, and several compounds derived from these plants were confirmed for their abilities to bind to both enzymes through molecular docking study. A study of Hibiscus sabdariffa L. (Roselle) found that the extract had antioxidant activity against DPPH (76.79%) and ABTS (34.37%), as well as anti-collagenase (IC50 = 750.33 μg/mL), anti-elastase (IC50 = 103.83 μg/mL), and anti-hyaluronidase (IC50 = 619.43 μg/mL) properties.

Evidence strength: Strong mechanistic and in vitro evidence linking elastase overactivity to skin aging, photoaging, and inflammatory skin conditions. Clinical (human) evidence for elastase-targeted cosmeceutical interventions remains very limited and preliminary. Most anti-elastase plant extract data come from in vitro enzyme inhibition assays, not from controlled human trials.

4.4 Cardiovascular Disease and Vascular Biology

The original discovery of elastase arose from vascular biology research, and the elastase–elastin axis has continued to be studied in the context of arterial disease.

In recent years, it has been found that the elastase enzymes that directly function in the blood vessels come from specialized macrophages. A 2008 study showed that atherosclerotic plaques harbor elastase made by inflammatory cells such as neutrophils. It is thought that the extracellular matrix material degrades and becomes weakened, contributing to the pathology of arteriosclerosis.

The action of AAT is not limited to lung function, as AAT is a systemic protein with various anti-inflammatory and immunomodulatory properties. Patients with AATD often experience additional extrapulmonary manifestations associated with the Z allele, such as liver disease, panniculitis, and vasculitis. Reports have also linked AATD to vascular pathology, including aortic aneurysm disease with dissection, and increased cardiovascular risk. Evidence suggests that deficiency of functional AAT contributes to a range of cardiovascular diseases, resulting from the protease–antiprotease imbalance associated with AATD.

AATD is linked to COPD and emphysema. In addition to pulmonary manifestations, AATD has also been associated with vascular pathology due to excessive protease activity, tissue degradation, and vessel stiffening.

Evidence strength: Strong mechanistic and epidemiological association between NE/elastase overactivity and vascular pathology, particularly in AATD. Direct prospective clinical trials specifically targeting elastase in primary cardiovascular disease prevention are lacking.

4.5 Sepsis, Acute Lung Injury, and Critical Illness

In many respiratory diseases characterized by an intense inflammatory response, the balance between proteolytic enzymes (proteases, including elastases) and their inhibitors is not neutral. Excess activity of neutrophil elastase (NE) and similar proteases has been reported to cause tissue damage and to alter the remodeling process in many clinical conditions such as pneumonia, respiratory distress, and acute lung injury (ALI).

Proteomic analysis and studies on the functional activity of human NETs indicate that NE is the most abundant non-histone protein and the predominant entity responsible for the NET "proteolytic signature." NE is a well-established mediator of alveolo-capillary permeability, where it is thought to trigger microvascular injury through primarily catalyzing endothelial cell cadherin proteolysis.

The use of sivelestat confirmed the potential of targeting NE for the treatment of disorders such as acute lung injury, complications arising from myocardial surgery, organ transplantation, and several models of ischemia/reperfusion injury. However, as noted above, the large STRIVE trial tempered enthusiasm. Overall, patients treated with NE inhibitors seem to have significant variability in their response to the drugs, resulting in the poor results seen in these studies.

Evidence strength: Strong preclinical evidence; mixed clinical evidence. Sivelestat is approved in Japan and South Korea for ALI associated with systemic inflammatory response syndrome, but has not gained regulatory approval in the United States or European Union based on available clinical trial data.

4.6 Inflammatory Skin Conditions: Psoriasis and Atopic Dermatitis

Human neutrophil elastase is known to play multiple roles in the human body, but an increase in its activity may cause a variety of diseases. Elastase inhibitors may prevent the development of psoriasis, chronic kidney disease, respiratory disorders, immune disorders, and even cancers.

The activity of neutrophil elastase is increased on the surface of the diseased skin of patients with psoriasis, atopic dermatitis, and allergic contact dermatitis — pathologies characterized by leukocyte infiltration of the skin. These observations are largely derived from ex vivo and histological studies; large randomized clinical trials testing elastase inhibition specifically in these dermatological conditions have not been reported in the published peer-reviewed literature to date.

Evidence strength: Preliminary. Evidence is based on biomarker/mechanistic studies and small observational data. Human interventional trials in dermatology are lacking.

4.7 Anti-aging: Flavonoids as Natural Elastase Inhibitors

A substantial body of in vitro research has identified polyphenolic flavonoids — widely present in dietary plants — as natural inhibitors of elastase, with potential relevance to both skin aging and systemic inflammation. Among polyphenolic compounds, some flavonoids and their derivatives, which are mostly found in herbal plants, have been revealed to influence elastase release and its action on human cells. The inhibitory activity on elastase is a characteristic of flavonoid aglycones and their glycoside and methylated, acetylated, and hydroxylated derivatives.

Researchers have compared the inhibitory effects of structurally similar bioactive flavonoids — quercetin, hyperoside, luteolin, and luteoloside — on elastase activity and elucidated their mechanisms of action using enzyme inhibition assays and multiple spectroscopy approaches. Luteolin strongly inhibited elastase, followed by hyperoside, quercetin, and luteoloside.

Flavonoids are natural compounds with diverse bioactivities that inhibit elastase via specific molecular interactions, including hydrogen bonds, van der Waals interactions, and electrostatic forces, which collectively stabilize flavonoid binding within the enzyme's active site.

Although various synthetic inhibitors have been explored, natural products, particularly flavonoids, are gaining attention owing to their dual anti-inflammatory and enzymatic inhibitory activities. Compared to other natural inhibitors derived from traditional Chinese medicines, such as alkaloids and saponins, flavonoids have higher bioavailability and reduced toxicity at effective doses.

Evidence strength: Predominantly in vitro and in silico. The translation of flavonoid-mediated elastase inhibition to meaningful clinical anti-aging outcomes in humans has not been established in large randomized controlled trials.

5. Body Systems and Health Areas Associated with Elastase

Digestive / Gastrointestinal System: As part of the digestive enzymes secreted by the pancreas, elastase contributes to the breakdown of dietary proteins, aiding in nutrient absorption. Fecal elastase-1 serves as a primary clinical biomarker for exocrine pancreatic function.
Pulmonary / Respiratory System: In many respiratory diseases, excess activity of neutrophil elastase causes tissue damage and alters the remodeling process in conditions such as pneumonia, respiratory distress, and acute lung injury. It is pivotal in the pathogenesis of emphysema and COPD, particularly in AATD.
Immune System: Neutrophil azurophilic granules contain NE, and due to its antimicrobial and immunomodulatory function, it plays a major role in the physiological response to infection.
Cardiovascular System: Elastase activity within arterial walls is implicated in atherosclerotic plaque progression and in AATD-associated vascular complications including aortic aneurysm. AATD has been associated with vascular pathology due to excessive protease activity, tissue degradation, and vessel stiffening.
Integumentary System (Skin): In photoaged skin, the elastic fibers of the upper dermis are degraded by elastolytic enzymes including MMPs and neutrophil elastases. Overactivity of elastase contributes to wrinkling and loss of dermal elasticity.
Connective Tissue / Extracellular Matrix: Elastase helps in the remodeling of extracellular matrix proteins, facilitating tissue repair and regeneration.
Renal System: Elastase inhibitors may prevent the development of chronic kidney disease, and NE overactivity has been implicated in sepsis-associated acute kidney injury.

6. Dosage Forms and Dosages Reported in Studies

Elastase, as a natural ingredient or dietary supplement, is not consumed in the same way as a botanical extract. Its practical dosing context falls into three distinct categories: (1) as a pancreatic digestive enzyme in enzyme replacement products, (2) as a research/pharmaceutical agent, and (3) as a biomarker measured in stool or serum.

6.1 Diagnostic (Fecal Elastase)

In diagnostic studies, fecal elastase-1 at a cut-off of 200 μg/g showed a pooled sensitivity and specificity of 0.94 and 0.69, respectively; lowering the cut-off to 100 μg/g improved specificity to 0.82 but decreased sensitivity to 0.88. Pancreatic elastase concentrations below 100 mcg/g are consistent with exocrine pancreatic insufficiency.

6.2 Pharmaceutical Research (NE Inhibitors)

In pharmaceutical studies involving the NE inhibitor sivelestat as a proxy for understanding the effects of modulating elastase activity:

In a rat model of sepsis, sivelestat was evaluated at 0.2 g/kg body weight, administered intravenously at 24 hours post-treatment.

Sivelestat is the most effective elastase inhibitor used in clinical practice. However, sivelestat is expensive, causes numerous side effects, and has a limited long-term safety profile. Therefore, cheaper and safer elastase inhibitors are needed.

6.3 In Vitro Flavonoid Studies

Anti-elastase effects of natural flavonoids are typically reported as IC50 values (concentration inhibiting 50% of enzyme activity). Roselle (Hibiscus sabdariffa) extract demonstrated anti-elastase activity with an IC50 of 103.83 μg/mL, while other plant extracts have shown elastase inhibition at IC50 values of 45.35 μg/mL. These values are from in vitro assays and have not been directly translated into human oral dosing recommendations for elastase inhibition.

Despite their diverse natural sources, peptide elastase inhibitors show IC50 values in a range from nM to μM.

No standardized human oral dosage for elastase as a dietary supplement ingredient has been established in peer-reviewed clinical literature.

7. Safety Considerations and Interactions

7.1 Immunogenicity of Porcine-Derived Elastase

With the administration of porcine elastase to human beings, there is the risk of antibody formation due to the antigenic effect of the foreign protein. There is therefore the danger of anaphylaxis with repeated administration. Accordingly, human elastase is preferable for human use. This is a material safety concern for any therapeutic preparation derived from porcine pancreatic tissue.

7.2 Risk of Uninhibited Elastase Activity: A1AT Deficiency

Alpha-1 antitrypsin deficiency (A1AD) leads to uninhibited destruction of elastic fibre by elastase; the main result is emphysema. Individuals with A1AT deficiency are at particular risk from any intervention — including environmental exposures such as cigarette smoke — that further increases elastase activity or decreases endogenous inhibitor levels.

7.3 Overactivity and Disease Promotion

An increase in human neutrophil elastase activity may cause a variety of diseases. Elastase inhibitors may prevent the development of psoriasis, chronic kidney disease, respiratory disorders, immune disorders, and even cancers. This underscores that exogenous administration of elastase — as opposed to its inhibition — carries significant pathophysiological risks when not tightly regulated.

Excess activity of neutrophil elastase and similar proteases has been reported to cause tissue damage and to alter the remodeling process in many clinical conditions such as pneumonia, respiratory distress, and acute lung injury.

7.4 Findings from NE-Inhibitor Clinical Trials

The large multicenter, double-blind placebo-controlled STRIVE trial showed a trend toward increased long-term mortality with the NE inhibitor sivelestat compared to placebo (40.2% vs. 31.3%; P = .006) in ALI patients receiving mechanical ventilation. This finding illustrates that modulating elastase activity in critically ill patients carries risk and that simple inhibition of this enzyme does not uniformly confer benefit.

7.5 Interactions with Endogenous Inhibitors and Drugs

The most studied endogenous inhibitor is α1-AT; it is a protein molecule with molecular weight of 54 kDa and possesses high inhibitory capacity against many serine proteases, including neutrophil elastase. Pharmacological agents that affect serine protease activity broadly — including some anticoagulants and anti-inflammatory drugs — may theoretically interact with the elastase–antiprotease equilibrium, though specific drug–elastase interaction data from clinical studies are not extensively documented in the public literature.

7.6 Tissue Remodeling Considerations

Because elastin is found in highest concentrations in the elastic fibers of connective tissues, elastase is frequently used to dissociate tissues that contain extensive intercellular fiber networks. For this purpose, it is usually used with other enzymes such as collagenase, trypsin, and chymotrypsin. This context — primarily laboratory use — highlights the potency of elastase as a tissue-degrading agent and underscores why unregulated in vivo activity is pathologically significant.

References

Health Conditions

Health conditions that Elastase may help support.

No conditions available.

Body Systems

Body systems that Elastase may help support.

No body systems available.